Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Prepaid Assets (2019 - 2025)

Allogene Therapeutics' Prepaid Assets history spans 7 years, with the latest figure at $8.5 million for Q3 2025.

  • For Q3 2025, Prepaid Assets fell 33.66% year-over-year to $8.5 million; the TTM value through Sep 2025 reached $8.5 million, down 33.66%, while the annual FY2024 figure was $10.9 million, 4.72% up from the prior year.
  • Prepaid Assets for Q3 2025 was $8.5 million at Allogene Therapeutics, down from $9.5 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $22.5 million in Q2 2022 and bottomed at $7.9 million in Q3 2023.
  • The 5-year median for Prepaid Assets is $11.5 million (2025), against an average of $13.2 million.
  • The largest annual shift saw Prepaid Assets surged 1548.0% in 2021 before it plummeted 55.01% in 2023.
  • A 5-year view of Prepaid Assets shows it stood at $14.0 million in 2021, then decreased by 17.95% to $11.5 million in 2022, then fell by 9.44% to $10.4 million in 2023, then increased by 4.72% to $10.9 million in 2024, then dropped by 21.86% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Prepaid Assets are $8.5 million (Q3 2025), $9.5 million (Q2 2025), and $11.5 million (Q1 2025).